Median progression-free survival was significantly longer in the panobinostat group than in the placebo group ( 1199 months [ 95 % CI 1033-1294 ] vs 808 months [ 756-923 ] ; hazard ratio [ HR ] 063 , 95 % CI 052-076 ; p < 00001 ) .